---
title: "Johnson & Johnson Gets FDA Approval for Imaavy to Treat Warm Autoimmune Hemolytic Anemia"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296840164.md"
description: "Johnson & Johnson received FDA approval for Imaavy (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia in adults and children aged 12 and older who have used corticosteroids. It is the first therapy proven safe and effective for this rare disease, marking a significant milestone for an underserved patient community."
datetime: "2026-08-25T00:12:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296840164.md)
  - [en](https://longbridge.com/en/news/296840164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296840164.md)
generator: "portal-rs"
---

# Johnson & Johnson Gets FDA Approval for Imaavy to Treat Warm Autoimmune Hemolytic Anemia

By Elias Schisgall

Johnson & Johnson received approval from the Food and Drug Administration for Imaavy to treat a rare autoantibody disease in adults and children at least 12 years old who previously took or are currently taking corticosteroids. 

The company said the drug, also known as nipocalimab-aahu, is now the first therapy to be proven safe and effective to specifically treat the disease, called warm autoimmune hemolytic anemia. 

The drug had undergone FDA priority review, Johnson & Johnson said. 

"Today's announcement marks the second approval for Imaavy and is an extraordinary milestone for people living with warm autoimmune hemolytic anemia, an underserved community that has waited far too long for an FDA-approved treatment," Johnson & Johnson's global immunology therapeutic area head, David Lee, said on Monday. 

Write to Elias Schisgall at elias.schisgall@wsj.com 

(END) Dow Jones Newswires

August 24, 2026 20:06 ET (00:06 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Trinity Legacy Partners LLC Sells 4,917 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/296589986.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Vest Financial LLC Sells 103,567 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/296462162.md)
- [Lakefront Biotherapeutics wins FDA orphan drug status for gamgertamig in pemphigus](https://longbridge.com/en/news/296823553.md)
- [14:06 ETStarlight Children's Foundation Announces 2026 Starlight Awards Honorees](https://longbridge.com/en/news/296524956.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**